AddedRisk Factors
We operate in a global economy, which includes utilizing third-party suppliers in several countries outside the United States. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty. The U.S. government has recently announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the pharmaceutical industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. These developments have created a dynamic and unpredictable trade landscape, which may adversely impact our business, results of operations, financial condition and prospects.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for clinical testing, as well as for manufacture of any products that we may commercialize, if approved. Currently, several of our suppliers are located outside of the United States, and our principal suppliers of certain raw materials are located outside of the United States. The active pharmaceutical ingredients (APIs) for cretostimogene is manufactured in the United States, and cretostimogene is manufactured in the United States. We also rely on specialized laboratory equipment, supplies, materials, and precursor compounds, all or part of which we believe may be ultimately sourced from multiple countries outside the United States, to advance our research and development efforts.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs, raw materials, laboratory equipment and research materials and components. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting our ability to secure additional financing on favorable terms or at all. In addition, as we advance toward commercialization in the future, tariffs and trade restrictions could hinder our ability to establish cost-effective production capabilities, negatively impacting our growth prospects.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt non-tariff measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit our ability to compete internationally and attract non-U.S. investment, employees, customers and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased enforcement actions, or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedRisk Factors
•Because cretostimogene is an investigational product candidate and has not received FDA approval, our third party contract manufacturers have not produced cretostimogene at commercial levels and have not yet successfully passed the necessary regulatory inspections to produce cretostimogene for commercial use.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Since its enactment, there have been executive, judicial and Congressional challenges and amendments to certain aspects of the ACA.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, on August 16, 2022, the IRA was signed into law. Among other things, the IRA (i) directs HHS to negotiate the price of certain high-expenditure, single-source biologics that have been on the market for at least 11 years covered under Medicare (the “Medicare Drug Price Negotiation Program”) and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 15, 2024, HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering. However, if certain events occur prior to the end of such five-year period, including if we become a “large accelerated filer”, as defined under the Exchange Act, our annual gross revenue exceeds $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley);
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting the public;
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this exemption and, therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
(ANI) naming filed a complaint against us as defendant, in the Superior Court of the State of Delaware seeking (i) a declaratory judgement judgment that a provision in an assignment and technology transfer agreement between us and ANI (formerly BioSante Pharmaceuticals, Inc.), dated November 15, 2010, 2010 (the ANI Agreement), obligates us to pay ANI 5% of worldwide net sales of cretostimogene. cretostimogene, and (ii) compensatory damages alleging we were unjustly enriched by obtaining the benefit of certain non-patent assets without paying adequate consideration to ANI.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we have completed a Phase 2 clinical trial for cretostimogene and have reported topline data from the Phase 3 BOND-003 Cohort C trial for cretostimogene, we We have not as an organization completed the pivotal clinical trials for cretostimogene or submitted submission of a BLA, and we may be unable to do so for cretostimogene or any future product candidates.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If UGN-102 or TAR-200 receives FDA approval and enter the bladder cancer market prior to the approval of cretostimogene, the The market for cretostimogene may be adversely affected and our opportunity to generate revenue from the sale of cretostimogene, if approved, could be adversely affected. affected by the prior entry of other treatments for bladder cancer.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we continue to believe the allegations are without merit and intend to vigorously defend this matter, such litigation could result in substantial costs and divert our management’s attention from other business concerns, cause us reputational damage, negatively affect our stock price and result in monetary damages and future royalty obligations, if and to the extent cretostimogene receives regulatory approval. damages.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We rely on a third-party manufacturer for the production of cretostimogene and a third-party manufacturer for the production of DDM, and expect to continue to rely on third-party these manufacturers for commercial manufacture if cretostimogene or any future product candidates receive regulatory approval.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, on October 15, 2024, UroGen announced that the FDA accepted UroGen’s NDA for UGN-102 approved Zusduri (intravesical mitomycin/sterile hydrogel) in LG-IR-NMIBC, and set a PDUFA action date of LG-IR-NMIBC in June 13, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We will Although we have completed the Phase 3 BOND-003 Cohort C trial for cretostimogene, we may need to successfully complete later-stage and additional later-stage, pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market cretostimogene or any future product candidates.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, Johnson & Johnson announced on January 15, 2025 that it initiated the submission of an NDA with the FDA received approval for TAR-200 Inlexzo for the treatment of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with CIS, with or without papillary tumors.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we later switch third-party manufacturers, we may be unable to demonstrate comparability between lots produced previously and those produced by such new third-party manufacturers, in which case we may be required to gather additional data utilizing material produced by such new third-party manufacturers before we are able to complete our BLA submission for cretostimogene or submit a BLA additional BLAs for cretostimogene, cretostimogene or any future product candidate, if ever.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Should any of the foregoing occur, it could International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We Other than Biovire, which manufactures and conducts release testing of our cretostimogene drug product, we do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing capabilities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We believe, based on our current operating plan, that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations into for at least the first half next twelve months from the date of 2028. this Annual Report.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Use of cretostimogene or any future product candidates could be associated with adverse side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials, abandon cretostimogene or any future product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Additionally, our discussion and analysis below are focused on our financial results and liquidity and capital resources for the years ended December 31, 2025 and 2024, including year-over-year comparisons of our financial performance and condition for these years. Discussion and analysis of the year ended December 31, 2023 specifically, as well as the year-over-year comparison of our financial performance and condition for the years ended December 31, 2024 and 2023, are located in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Annual Report for the year ended December 31, 2024, as filed with the SEC on March 28, 2025, which is incorporated herein by reference.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We are evaluating the safety and efficacy of cretostimogene as a monotherapy in BOND-003 Cohort C, our ongoing Phase 3 clinical trial in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS), with or without Ta/T1 disease. Given the limitations of currently approved therapies, the next course of treatment for these patients with BCG-unresponsive tumors is radical cystectomy, which is the complete removal of the bladder. This surgery carries a significant social, functional and emotional burden for patients. As such, there is a significant unmet need for effective bladder-sparing treatments. We have completed enrollment for this cohort and reported potentially best-in-disease data in September 2025. This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we initiated in the fourth quarter of 2025 and expect to complete in 2026. Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for the treatment of high-risk BCG-unresponsive NMIBC with CIS with or without Ta or T1 papillary tumors. Additionally, in April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC with only Ta/T1 disease. Initial data from this Cohort was reported at the 2025 AUA Annual Meeting, with potentially best-in-disease data reported at the Society of Urologic Oncology (SUO) 26th Annual Meeting in December 2025. Based on internal research derived from the National Cancer Institute Surveillance, Epidemiology, and End Results Program’s (NIH SEER) database, secondary claims data analytics and management assumptions, the high-risk BCG-unresponsive NMIBC segment may represent up to 25,000 addressable patients.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We are also conducting a Phase 3 clinical trial, PIVOT-006, the first randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC assessing adjuvant cretostimogene following transurethral resection of the bladder tumor (TURBT), with enrollment completed in the third quarter of 2025. These patients with intermediate-risk NMIBC are encumbered by frequent tumor recurrence that requires repeat resection of the bladder tumors. Moreover, intravesical BCG is no longer recommended by guidelines for this patient population due to the continuous BCG shortage. We believe cretostimogene, if approved in intermediate-risk NMIBC, has the potential to serve as a first-in-class backbone therapy in this frontline adjuvant setting, for which there are currently no U.S. FDA approved options. Based on internal research derived from NIH SEER database, secondary claims data analytics and management assumptions, the intermediate-risk NMIBC segment may represent up to 50,000 addressable patients.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In February 2025, the Company's wholly owned subsidiary, SafeGuard Healthcare, LLC (SafeGuard), established a note receivable with an initial principal amount of $25.0 million through a convertible promissory note (Note) from SP Healthcare SPV I, LLC (the SPV). The SPV used the proceeds from the Note to make an investment in Biovire for the purpose of Biovire acquiring substantially all of the assets of a contract manufacturing organization that provides clinical supply of cretostimogene to the Company. On July 20, 2025, following the conversion of the Note triggered by the cessation of services by SkyPath to the SPV and Biovire (Conversion Event), we, through our subsidiary, SafeGuard, obtained control of the SPV and Biovire. As a result of this change in control, the operations of Biovire were consolidated as of the effective date of the conversion.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the Conversion Event, we obtained control of the SPV and its subsidiary, Biovire, a contract manufacturer specializing in the fill and finish of novel drugs and medical devices for pharmaceutical and biotech companies. Our commercial and development revenue consists of Biovire's fill and finish of novel drugs and medical devices.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Cost of sales reflects the direct cost of labor and other overhead, which includes direct manufacturing, production, and packaging materials for commercial and development product sales.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On March 28, 2025, we entered into the Jefferies Sales Agreement with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, shares of our common stock. On the same day, we filed a shelf registration statement on Form S-3ASR with the SEC, which contains a base prospectus, covering an unlimited amount of our common stock, preferred stock, debt securities and warrants to purchase any of such securities, and a sales agreement prospectus, which we subsequently amended on January 13, 2026, covering the offering, issuance and sale of up to a maximum aggregate offering price of $550 million of our common stock that may be issued and sold from time to time under the Jefferies Sales Agreement. During the year ended December 31, 2025, 3,859,118 shares were sold under the shelf registration statement or the Jefferies Sales Agreement, at a weighted-average price of $38.99 per share. Through December 31, 2025, the Company received net proceeds of $147.1 million, after deducting discounts and commissions and other offering expenses. Subsequent to December 31, 2025, the Company received net proceeds of $188.0 million under the Jefferies Sales Agreement, after deducting discounts and commissions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
In anticipation of potential FDA approval, we are actively building our commercial operations, marketing, market access and patient access and field force capabilities. This includes pre-launch activities currently being executed, including scientific communication activities and engagements by our field medical organization. We are also implementing strategic initiatives to build seamless product distribution and patient support. Our efforts are focused on ensuring that we are fully prepared to launch and deliver cretostimogene to patients and healthcare providers, if approved. We are evaluating the safety and efficacy of cretostimogene, as a monotherapy, in BOND-003 Cohort C, our ongoing Phase 3 clinical trial in high-risk BCG-unresponsive NMIBC with CIS and with or without Ta/T1 disease. We have completed enrollment for this cohort and reported interim data at the American Urological Association’s 2024 Annual Meeting in May 2024, and topline data at the 2024 SUO Annual Meeting in in December 2024, which was updated at the 40th Annual EAU Congress. We believe that this trial could serve as the basis for a BLA submission to the U.S. FDA, which we expect to initiate in the second half of 2025. Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for the treatment of High-Risk BCG-unresponsive NMIBC with CIS with or without Ta or T1 tumors.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedMD&A
Other (expense) income consists of miscellaneous items, such as debt extinguishment due to early payoff of loan and other items not related to our core operations.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedMD&A
We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RemovedMD&A
We are an emerging growth company, as defined in the JOBS Act. The JOBS Act permits an emerging growth company such as us to take advantage of an extended transition period to comply with new or revised accounting standards. We have elected to avail ourselves of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at the time private companies adopt the new or revised standard and may do so until such time that we either (i) irrevocably elect to opt out of such extended transition period or (ii) no longer qualify as an emerging growth company. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. We will continue to remain an emerging growth company until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235 billion; (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.
Read it in 10-K Mar 28, 2025 at sec.govopen_in_new
RewordedMD&A
The increase of $23.8 $39.8 million in general and administrative expenses for the year ended December 31, 2024 2025 was primarily due to an increase in compensation costs of $14.9 $17.9 million due to increased headcount, including a $6.9 $9.5 million increase in stock-based compensation, as well as and increased professional and consultant fees of $3.7 $14.3 million, which includes a $8.5 million related to legal, accounting and consulting increase in legal fees, as well as an increase in marketing-related costs of $2.3 million, $2.2 million and an increase in insurance other general fees and costs of $1.4 $7.6 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, net cash provided by financing activities was $628.3 million, consisting primarily of net proceeds from the IPO initial public offering and follow-on public offering of $403.0 million and $223.1 million, respectively, net of issuance costs and deferred offering costs. stock issuance costs, as well as proceeds from the exercise of common stock options of $2.6 million, partially offset by the long-term debt success fee payoff of $0.4 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The increase of $36.4 $34.5 million in R&D expenses for the year ended December 31, 2024 2025 was primarily due to an increase of $26.5 $17.5 million in external clinical trial expenses related to higher CRO fees as patient enrollment increased and higher CMC, increased, as well as an increase of $8.5 $13.5 million in compensation costs due to increased headcount, including a $5.7 million increase in stock-based compensation, and higher facilities, fees an increase in other research and other related development costs of $1.3 $3.5 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, net cash used in operating activities used $78.7 million of cash, was $132.3 million, primarily resulting from our net loss of $88.0 million and $161.0 million, as well as accretion of the discount on short-term investments of $5.0 $1.0 million, partially offset by non-cash stock-based compensation charges of $11.4 $26.7 million and net cash used in provided by changes in our operating assets and liabilities of $2.9 $2.3 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Cretostimogene, Cretostimogene is currently in clinical development for the treatment of patients with high-risk NMIBC who are unresponsive and intermediate-risk non-muscle invasive bladder cancer (NMIBC), which potentially represents up to BCG therapy, the current standard-of-care for high-risk NMIBC. 150,000 addressable patients.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, net cash used in investing activities was $300.8 $245.8 million, primarily due to $1,067.9 million of purchases of marketable securities and $22.0 million, net of cash acquired, for the acquisition of SPV and Biovire through the Conversion Event, partially offset by proceeds from sales and maturities of short-term investments.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Through December 31, 2024, 2025, we have received aggregate gross proceeds of approximately $982.9 million $1.1 billion from the sale of shares of our common stock through public offerings from our IPO, our follow-on offering in December 2024, and our at-the-market facility, and sales of our redeemable convertible preferred stock.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
License and collaboration revenue was $0.8 million for the year ended December 31, 2025 compared to $1.1 million for the year ended December 31, 2024 compared to $0.2 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
During the years ended December 31, 2024 2025 and 2023, 2024, we recorded $1.0 $0.8 million and less than $0.1 $0.2 million, respectively, in license and collaboration revenue related to the Lepu Kissei License Agreement, as well as $0.2 zero and $1.0 million related to the Kissei Lepu License Agreement in both years. Agreement, respectively.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
R&D expenses were $116.6 million for the year ended December 31, 2025 compared to $82.1 million for the year ended December 31, 2024 compared to $45.8 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
General and administrative expenses were $73.5 million for the year ended December 31, 2025 compared to $33.7 million for the year ended December 31, 2024 compared to $9.9 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
We intend to add In addition, in April 2025, we initiated a third Cohort to CORE-008, (Cohort CX), evaluating cretostimogene in a combination therapy with gemcitabine in both the high-risk BCG-exposed and BCG-unresponsive population.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new